Literature DB >> 11707444

Differential regulation of Akt kinase isoforms by the members of the TCL1 oncogene family.

Jarmo Laine1, Gerald Künstle, Toshiyuki Obata, Masayuki Noguchi.   

Abstract

The members of the TCL1 proto-oncogene family (TCL1, MTCP1, and TCL1b) bind to Akt1, increasing its phosphorylation status and kinase activity. This is thought to be secondary to the formation of TCL1-Akt oligomers within which Akt is preferentially phosphorylated. Here we show that, in contrast to Akt1 and Akt2, which bind to all members of the TCL1 family, Akt3 specifically interacts with TCL1 but not with MTCP1 or TCL1b. This association is functional, as the presence of TCL1 but not MTCP1 or TCL1b increased Akt3 kinase activity in in vitro kinase assays. Functional specificity is determined by the Akt pleckstrin homology domain as chimeric Akt1, where Akt1 PH domain was replaced by that of Akt3 was no longer able to interact with MTCP1 or TCL1b and its kinase activity was solely enhanced by TCL1. Moreover, we show that, in TCL1-overexpressing SUPT-11 T-cell leukemia and P3HR-1 Burkitt's lymphoma cell lines, TCL1 interacts with endogenous Akt1, Akt2, and Akt3. TCL1 enhanced hetero-oligomerization of Akt1 with Akt3 and as a consequence facilitated transphosphorylation of Akt molecules, which may contribute to Akt activation and TCL1-induced leukemogenesis in vivo.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11707444     DOI: 10.1074/jbc.M107069200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  33 in total

Review 1.  Inhibition of Akt with small molecules and biologics: historical perspective and current status of the patent landscape.

Authors:  Margrith E Mattmann; Sydney L Stoops; Craig W Lindsley
Journal:  Expert Opin Ther Pat       Date:  2011-06-02       Impact factor: 6.674

2.  Interaction of human biliverdin reductase with Akt/protein kinase B and phosphatidylinositol-dependent kinase 1 regulates glycogen synthase kinase 3 activity: a novel mechanism of Akt activation.

Authors:  Tihomir Miralem; Nicole Lerner-Marmarosh; Peter E M Gibbs; Jermaine L Jenkins; Chelsea Heimiller; Mahin D Maines
Journal:  FASEB J       Date:  2016-05-10       Impact factor: 5.191

3.  PI3K/Akt signaling pathway is involved in the pathogenesis of ulcerative colitis.

Authors:  Xiao Li Huang; Jin Xu; Xiao Hui Zhang; Bo Yun Qiu; Lan Peng; Meng Zhang; Hua Tian Gan
Journal:  Inflamm Res       Date:  2011-03-26       Impact factor: 4.575

4.  TCL1A gene involvement in T-cell prolymphocytic leukemia in Japanese patients.

Authors:  Akihiko Yokohama; Akio Saitoh; Hirotaka Nakahashi; Takeki Mitsui; Hiromi Koiso; Yoshitora Kim; Hideki Uchiumi; Takayuki Saitoh; Hiroshi Handa; Takahiro Jimbo; Kayoko Murayama; Tohru Sakura; Hirokazu Murakami; Masamitsu Karasawa; Yoshihisa Nojima; Norifumi Tsukamoto
Journal:  Int J Hematol       Date:  2011-12-23       Impact factor: 2.490

5.  Dysregulated TCL1 promotes multiple classes of mature B cell lymphoma.

Authors:  Katrina K Hoyer; Samuel W French; Devin E Turner; Mai T N Nguyen; Mathilde Renard; Cindy S Malone; Sonja Knoetig; Chen-Feng Qi; Thomas T Su; Hilde Cheroutre; Randolph Wall; David J Rawlings; Herbert C Morse; Michael A Teitell
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-14       Impact factor: 11.205

6.  Identification of small proline-rich repeat protein 3 as a novel atheroprotective factor that promotes adaptive Akt signaling in vascular smooth muscle cells.

Authors:  Amanda K Segedy; Amy L Pyle; Bin Li; Youmin Zhang; Vladimir R Babaev; Parmjit Jat; Sergio Fazio; James B Atkinson; MacRae F Linton; Pampee P Young
Journal:  Arterioscler Thromb Vasc Biol       Date:  2014-10-02       Impact factor: 8.311

Review 7.  Recent development of anticancer therapeutics targeting Akt.

Authors:  John K Morrow; Lei Du-Cuny; Lu Chen; Emmanuelle J Meuillet; Eugene A Mash; Garth Powis; Shuxing Zhang
Journal:  Recent Pat Anticancer Drug Discov       Date:  2011-01       Impact factor: 4.169

Review 8.  The PTEN-AKT3 signaling cascade as a therapeutic target in melanoma.

Authors:  Subbarao V Madhunapantula; Gavin P Robertson
Journal:  Pigment Cell Melanoma Res       Date:  2009-05-28       Impact factor: 4.693

9.  Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors.

Authors:  Stanley F Barnett; Deborah Defeo-Jones; Sheng Fu; Paula J Hancock; Kathleen M Haskell; Raymond E Jones; Jason A Kahana; Astrid M Kral; Karen Leander; Ling L Lee; John Malinowski; Elizabeth M McAvoy; Debbie D Nahas; Ronald G Robinson; Hans E Huber
Journal:  Biochem J       Date:  2005-01-15       Impact factor: 3.857

10.  High TCL1 expression and intact T-cell receptor signaling define a hyperproliferative subset of T-cell prolymphocytic leukemia.

Authors:  Marco Herling; Kaushali A Patel; Michael A Teitell; Marina Konopleva; Farhad Ravandi; Ryuji Kobayashi; Dan Jones
Journal:  Blood       Date:  2007-09-21       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.